Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01499160 | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | terminated | Phase 2 | 7 | University of Maryland, BaltimoreOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT02236572 | Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | terminated | Phase 2 | 17 | Yale UniversityOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT00925652 |
| Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer(ABCDE) |
| terminated |
| Phase 2 |
| 55 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Jan 19, 2022 |
| clinicaltrials |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | terminated | Phase 2 | 29 | BerGenBio ASAINDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT03499353 | Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | terminated | Phase 2 | 61 | PfizerINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT04298918 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 8, 2021 | clinicaltrials |
| NCT01934335 | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | terminated | Phase 2 | 12 | Ronald WeigelOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT02213042 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 13, 2021 | clinicaltrials |
| NCT00110136 | St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer | terminated | Phase 2 | 9 | Wake Forest University Health SciencesOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | terminated | Phase 2 | 78 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02833766 | Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer | terminated | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02907918 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer(PALTAN) | terminated | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | terminated | Phase 2 | 16 | PfizerINDUSTRY | 7 | Sep 27, 2021 | clinicaltrials |
| NCT03894007 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer(PREDIXIIHER2) | terminated | Phase 2 | 6 | Renske AltenaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT03795012 | Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | terminated | Phase 2 | 22 | MedSIROTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01988090 | High Dose Vitamin D vs Standard Dose Vitamin D Study | terminated | Phase 2 | 93 | Mothaffar RimawiOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03858972 | Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC(CONTESSA 2) | terminated | Phase 2 | 152 | Odonate Therapeutics, Inc.INDUSTRY | 6 | Jul 30, 2021 | clinicaltrials |
| NCT03952325 | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC(CONTESSA TRIO) | terminated | Phase 2 | 294 | Odonate Therapeutics, Inc.INDUSTRY | 3 | Jul 30, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT00542191 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | terminated | Phase 2 | 30 | Leo W. Jenkins Cancer CenterOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT01220128 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer(INDUCT) | terminated | Phase 2 | 66 | GlaxoSmithKlineINDUSTRY | 7 | May 25, 2021 | clinicaltrials |
| NCT03983395 | Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Ichnos Sciences SAINDUSTRY | 1 | May 24, 2021 | clinicaltrials |
| NCT01861054 | Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer | terminated | Phase 2 | 20 | Dompé Farmaceutici S.p.AINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT03051672 | Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02569801 | A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy(HydranGea) | terminated | Phase 2 | 71 | Genentech, Inc.INDUSTRY | 6 | Apr 23, 2021 | clinicaltrials |
| NCT00461773 | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 5 | Yale UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT00470249 | Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer | terminated | Phase 2 | 5 | University of SouthamptonOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02362230 | Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy | terminated | Phase 2 | 26 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT00090844 | Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer | terminated | Phase 2 | 49 | University of South FloridaOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT00448266 | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | terminated | Phase 2 / Phase 3 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)(TRAXHER2) | terminated | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 12 | Jan 22, 2021 | clinicaltrials |
| NCT02677714 | 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer | terminated | Phase 2 | 14 | Advanced Accelerator ApplicationsINDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT01495247 | Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 8, 2020 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | terminated | Phase 2 | 32 | GTxINDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT00796107 | A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer | terminated | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer(BATON-BC) | terminated | Phase 2 | 30 | AVEO Pharmaceuticals, Inc.INDUSTRY | 10 | Oct 27, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00138125 | Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer | terminated | Phase 2 | 2 | Translational Oncology Research InternationalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00622466 | Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | terminated | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00751101 | Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer | terminated | Phase 2 | 24 | University of California, San FranciscoOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00536939 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | terminated | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Feb 11, 2022source: clinicaltrials